Pervasive Developmental Disorder 

  • Author: Sufen Chiu, MD, PhD; Chief Editor: Caroly Pataki, MD   more...
 
Updated: Jun 7, 2011
 

Background

Pervasive developmental disorders (PDDs) include a spectrum of behavioral problems commonly associated with autism. The Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) includes autistic disorder, Rett syndrome, childhood disintegrative disorder, Asperger disorder, and PDD not otherwise specified under the spectrum of PDD.[1]

The DSM-IV groups these disorders together because they share behavioral problems in the area of social interaction and communication. Other symptoms include stereotyped behaviors, restrictive interests or activities, and cognitive deficits. (See History.)

Autistic disorder in its most severe presentation may describe a child aged 3 years who presents with no expressive language, who seeks comfort from parents in atypical ways, who engages in repetitive hand flapping, and who makes no eye contact. In the mildest presentation, PDD not otherwise specified may describe a child aged 9 years with poor peer interactions, normal verbal abilities, and mild nonverbal disabilities. The mild nonverbal disabilities make it difficult for the child to follow subtle social cues that most children easily interpret as anxiety, anger, or sadness. The child's preoccupation with a restricted interest and attention to detail often tires the patience of peers with similar interests who are developing normally. (See History, Etiology.)

Symptoms of PDDs that may begin during the first year of life include lack of joint attention. A normally developing 1-year-old infant would make eye contact with a parent, point at an object for the parent to see, and smile responsively if the parent identifies the object. A child at risk for PDD often lacks these behaviors. Some such children may escape clinical attention until adolescence. Adolescents with normal development begin to use abstract thinking, realize that people have differing opinions, and learn to accept them. Adolescents with PDD often present with rigid thinking, are unable to accept other's opinions, and explode behaviorally when they cannot convince others to adhere only to their opinion.

DSM-V may exclude Rett syndrome from the group of PDDs, because a genetic etiology has been identified for this disorder. For this reason, the association of fragile X syndrome and autistic disorder has been debated.[2] Some clinicians and researchers argue that, because fragile X syndrome is a genetic disorder, individuals with this syndrome cannot have autistic disorder. Alternatively, some propose that the frequency of autistic disorder among individuals with fragile X syndrome is similar to that in individuals with intellectual disability.

Go to Autism, Asperger Syndrome, and PET Scanning in Autism Spectrum Disorders for complete information on these topics.

Associated morbidities

Identified organic disorders that occur with PDD include epilepsy (the most common medical condition associated with PDD), cerebral palsy, fragile X syndrome, fragile X premutation involvement, tuberous sclerosis, phenylketonuria, neurofibromatosis, Down syndrome, and congenital rubella. Roughly 30% of patients with PDD present with a known medical disorder.[3] Seizures are the most frequent comorbidity. Deletions or duplications (eg, 15q duplication) are the most common genetic abnormality associated with PDD.[4] (See Etiology.)

Autistic disorder is commonly comorbid with intellectual disability. Fragile X syndrome is the most common genetic cause of intellectual disability. Therefore, autistic disorder should be common in those with fragile X syndrome. Several studies have demonstrated an excess of autistic symptom clusters and clinical findings, such as larger head circumference, in individuals with fragile X syndrome greater than would be expected among persons with intellectual disability without a genetic etiology.[5] These features are absent in cases of fragile X syndrome without autism. Therefore, a subtype of fragile X syndrome may be a PDD behavioral phenotype. As evidence mounts that PDDs have biological origins, these genetic syndromes may be used as models to develop new treatment strategies for PDD. (See Etiology.)

Symptoms of obsessive-compulsive disorder (OCD) and attention deficit hyperactivity disorder (ADHD) are often present in patients with PDD. Some clinicians label the OCD and ADHD symptoms separately, whereas others include them as part of the presentation of PDD. Regardless of the approach, the symptoms of OCD and ADHD may be disabling and require treatment with standard approaches that include, but are not limited to, medications and behavioral therapy.

Aggression is a symptom not specific to any particular psychiatric disorder. The etiologies are broad and include constipation, depression, anxiety, psychosis, or adjustment disorder. Treatment requires clarification of etiology to help select medications and other appropriate therapies.

Sensory integrations disorder is not found in the DSM-IV or the International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10) but best captures the behavioral problems that result when individuals with PDD become disruptive because they react adversely to loud noises, tags on clothing, or textures of food. They may also be disruptive while trying to seek alternative methods of self-soothing, such as swinging, wrapping themselves in heavy blankets, or eating nonnutritive items. Identification of these sensory needs or deficits is integral to the behavioral management of individuals with PDD.

Milestone regression

Regression, or the loss of developmental milestones, was once a controversial finding in autistic disorder. Today, differing degrees of regression are recognized as part of the developmental presentation of autistic disorder.[6]

Major losses of developmental milestones suggest Rett Syndrome, childhood disintegrative disorder, or Landau-Kleffner syndrome.

Also see Acquired Epileptic Aphasia.

Next

Etiology

Researchers continue to identify multiple etiologies for the underlying pathophysiology of pervasive developmental disorder (PDD). Different levels of dysfunction in CNS systems are most likely involved. For example, at the molecular level, the type of serotonin-transporter gene promoter may modulate the severity of PDD or increase the risk for development of PDD.[7] Data from a blood genomic study have suggested that the immune system plays a role.[8] At the neuroanatomic level, preliminary brain imaging studies have shown differences that may manifest clinically as a larger head size.[9]

Environmental factors may also contribute to development of PDD, although mercury exposure and vaccinations have mostly been dismissed.

Changes in culture may explain some of the increased rates of PDD not otherwise specified. A study correlated increased time spent indoors with increased rates of PDD and suggested that this was caused by increased television viewing.[10] Television may reinforce repetitive behaviors in vulnerable children who, in a different era, would not have spent so much time with computer games and television programming that detract from interpersonal interactions.

Children with PDD may have other specific cognitive deficits, including central auditory processing problems, which imply distorted pathways between hearing and cortical processing. They may also have specific cognitive strengths. In isolated cases, these special cognitive talents lead to these individuals being labeled savants.

Some of these deficits and strengths may manifest as sensory integration issues. For example, children with PDD may have hyperacoustic hearing, predisposing them to act erratically around loud noises. The hyperacoustic hearing may enable some children with PDD to be gifted musicians.[11] Temple Grandin, a distinguished author and professor with Asperger disorder, writes about her need for increased tactile stimulation, which helped her develop a more humane way to move cattle.[12]

Children with fragile X syndrome have many of these cognitive deficits. The genetic and molecular basis of fragile X syndrome has been described in detail, supporting the premise that deficits in the protein encoded by the fragile X syndrome gene result in glutamate disturbance and abnormal neuronal axonal development.[13] The protein FMRP, encoded by the fragile X syndrome gene, may interact with other neurotransmitters or processes to cause autistic symptoms in fragile X syndrome more often than in other genetic syndromes or nonsyndromic intellectual disability.

Since the identification of the genetic abnormality in Rett syndrome, milder cases of Rett syndrome with smaller deletions have been identified.[14] Individuals with milder cases of Rett syndrome have better intellectual ability and more classic symptoms of autistic disorder. The genetic defect in Rett syndrome results in alterations in the power center equivalents of brain cells, also known as mitochondria.[15]

Previous
Next

Epidemiology

Incidence in the United States

A survey of existing literature by Fombonne in 2003 indicated that the rate for all forms of pervasive developmental disorder (PDD) was 30-60 cases per 10,000 population, while the rate for Asperger disorder was 2.5 cases for 10,000 population and the rate for childhood disintegrative disorder was 0.2 case per 10,000 population. Fombonne attributed an increase in prevalences over time to changes in case definitions and to improved awareness.[16]

An epidemiologic survey confirmed the prevalence of PDD disorders to be 1 in 150 children.[17]

The increase in reported cases of PDD probably results from an increased identification of cases that do not meet specific criteria for autistic disorder or Asperger disorder but are diagnosed as PDD not otherwise specified.

Available surveys lack sufficient proof to support an increase in the prevalence of autistic disorder.

International incidence

No evidence suggests that the international prevalence of PDD differs from the prevalence in the United States. However, the literature indicates that these disorders are identified at a later age in specific regions of the United States than in other countries.[18]

Race predilection

Race has not been implicated as a risk factor for PDD.

Sex predilection

Sex bias for PDD is significant. Autism and PDD not otherwise specified may be 5 times more common in boys than in girls. Asperger syndrome may be 10 times more common in boys than in girls.

Only Rett syndrome affects more girls than boys; in fact, Rett syndrome is rarely diagnosed in boys. However, new molecular testing for Rett syndrome indicates that the incidence of the condition is greater in boys than previously reported.

Age predilection

Autistic disorder carries an onset criterion; evidence of the disorder must be present by age 3 years. Rett syndrome and childhood disintegrative disorder are also usually apparent by age 3 years.

As noted earlier, PDDs are diagnosed relatively late in United States compared with other countries.[18] Within the United States, geographical differences in age of diagnosis present a significant public health challenge as evidence mounts to support early diagnosis and intervention.

Previous
Next

Patient Education

Many parents of children with pervasive developmental disorder (PDD) need legal guidance to help them understand their legal rights to benefits and services available from public schools and from the medical system.

For patient education information, see the Brain and Nervous System Center, as well as Autism and Asperger Syndrome.

Previous
 
 
Contributor Information and Disclosures
Author

Sufen Chiu, MD, PhD  Assistant Clinical Professor (Volunteer Faculty), University of California, Davis, School of Medicine; Consulting Staff, Child and Adolescent Psychiatry of Sacramento County; Consulting Staff, Sutter Center for Psychiatry; Consulting Staff, Transcultural Wellness Center

Sufen Chiu, MD, PhD is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, American Academy of Pediatrics, American Psychiatric Association, California Medical Association, and Sierra Sacramento Valley Medical Society

Disclosure: Nothing to disclose.

Coauthor(s)

Randi Jenssen Hagerman, MD, FAAP  Professor of Pediatrics, Medical Director MIND Institute, Endowed Chair in Fragile X Research, Division of Developmental/Behavioral Pediatrics, University of California Davis Medical Center

Randi Jenssen Hagerman, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Society of Human Genetics, Society for Developmental and Behavioral Pediatrics, Society for Pediatric Research, and Western Society for Pediatric Research

Disclosure: Roche Grant/research funds PI on study; Novartis Grant/research funds PI on study; Seaside therapeutics Grant/research funds PI on study; Johnson and Johnson Grant/research funds PI on study; Forest Grant/research funds PI on study; curemark Grant/research funds PI on study

Specialty Editor Board

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Caroly Pataki, MD  Professor of Clinical Psychiatry and Behavioral Sciences, Department of Psychiatry, Division Chair, Child and Adolescent Psychiatry, Keck School of Medicine of the University of Southern California

Caroly Pataki, MD is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, New York Academy of Sciences, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

References
  1. APA. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA; 1994.

  2. Rogers SJ, Wehner DE, Hagerman R. The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J Dev Behav Pediatr. Dec 2001;22(6):409-17. [Medline].

  3. Moeschler JB. Medical genetics diagnostic evaluation of the child with global developmental delay or intellectual disability. Curr Opin Neurol. Apr 2008;21(2):117-22. [Medline].

  4. Schroer RJ, Phelan MC, Michaelis RC, Crawford EC, Skinner SA, Cuccaro M, et al. Autism and maternally derived aberrations of chromosome 15q. Am J Med Genet. Apr 1 1998;76(4):327-36. [Medline].

  5. Chiu S, Wegelin JA, Blank J, Jenkins M, Day J, Hessl D, et al. Early acceleration of head circumference in children with fragile x syndrome and autism. J Dev Behav Pediatr. Feb 2007;28(1):31-5. [Medline].

  6. Rogers SJ. Developmental regression in autism spectrum disorders. Ment Retard Dev Disabil Res Rev. 2004;10(2):139-43. [Medline].

  7. Brune CW, Kim SJ, Salt J, Leventhal BL, Lord C, Cook EH Jr. 5-HTTLPR Genotype-Specific Phenotype in Children and Adolescents With Autism. Am J Psychiatry. Dec 2006;163(12):2148-56. [Medline].

  8. Gregg JP, Lit L, Baron CA, Hertz-Picciotto I, Walker W, Davis RA, et al. Gene expression changes in children with autism. Genomics. Jan 2008;91(1):22-9. [Medline].

  9. Redcay E, Courchesne E. When is the brain enlarged in autism? A meta-analysis of all brain size reports. Biol Psychiatry. Jul 1 2005;58(1):1-9. [Medline].

  10. Waldman M, Nicholson S, Adilov N, Williams J. Autism prevalence and precipitation rates in California, Oregon, and Washington counties. Arch Pediatr Adolesc Med. Nov 2008;162(11):1026-34. [Medline].

  11. Heaton P, Hudry K, Ludlow A, Hill E. Superior discrimination of speech pitch and its relationship to verbal ability in autism spectrum disorders. Cogn Neuropsychol. Sep 2008;25(6):771-82. [Medline].

  12. Grandin T. Thinking In Pictures: and Other Reports from My Life with Autism. Vintage. 1996.

  13. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, et al. Advances in the treatment of fragile X syndrome. Pediatrics. Jan 2009;123(1):378-90. [Medline]. [Full Text].

  14. Erlandson A, Hagberg B. MECP2 abnormality phenotypes: clinicopathologic area with broad variability. J Child Neurol. Sep 2005;20(9):727-32. [Medline].

  15. Kriaucionis S, Paterson A, Curtis J, Guy J, Macleod N, Bird A. Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Mol Cell Biol. Jul 2006;26(13):5033-42. [Medline]. [Full Text].

  16. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord. Aug 2003;33(4):365-82. [Medline]. [Full Text].

  17. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders--autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMWR Surveill Summ. Feb 9 2007;56(1):12-28. [Medline].

  18. Shattuck PT, Durkin M, Maenner M, Newschaffer C, Mandell DS, Wiggins L, et al. Timing of identification among children with an autism spectrum disorder: findings from a population-based surveillance study. J Am Acad Child Adolesc Psychiatry. May 2009;48(5):474-83. [Medline].

  19. Luyster R, Richler J, Risi S, Hsu WL, Dawson G, Bernier R, et al. Early regression in social communication in autism spectrum disorders: a CPEA Study. Dev Neuropsychol. 2005;27(3):311-36. [Medline].

  20. Chandler S, Charman T, Baird G, Simonoff E, Loucas T, Meldrum D, et al. Validation of the social communication questionnaire in a population cohort of children with autism spectrum disorders. J Am Acad Child Adolesc Psychiatry. Oct 2007;46(10):1324-32. [Medline].

  21. Robins DL, Fein D, Barton ML, Green JA. The Modified Checklist for Autism in Toddlers: an initial study investigating the early detection of autism and pervasive developmental disorders. J Autism Dev Disord. Apr 2001;31(2):131-44. [Medline].

  22. Wong V, Hui LH, Lee WC, Leung LS, Ho PK, Lau WL, et al. A modified screening tool for autism (Checklist for Autism in Toddlers [CHAT-23]) for Chinese children. Pediatrics. Aug 2004;114(2):e166-76. [Medline].

  23. Sicherer SH. Clinical aspects of gastrointestinal food allergy in childhood. Pediatrics. Jun 2003;111(6 Pt 3):1609-16. [Medline].

  24. Cunningham M, Cox EO. Hearing assessment in infants and children: recommendations beyond neonatal screening. Pediatrics. Feb 2003;111(2):436-40. [Medline].

  25. Shevell M, Ashwal S, Donley D, Flint J, Gingold M, Hirtz D, et al. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology. Feb 11 2003;60(3):367-80. [Medline].

  26. Newmeyer A, Cecil KM, Schapiro M, Clark JF, Degrauw TJ. Incidence of brain creatine transporter deficiency in males with developmental delay referred for brain magnetic resonance imaging. J Dev Behav Pediatr. Aug 2005;26(4):276-82. [Medline].

  27. Bryson SE, Rogers SJ, Fombonne E. Autism spectrum disorders: early detection, intervention, education, and psychopharmacological management. Can J Psychiatry. Sep 2003;48(8):506-16. [Medline].

  28. Wilkinson KM, Hennig S. The state of research and practice in augmentative and alternative communication for children with developmental/intellectual disabilities. Ment Retard Dev Disabil Res Rev. 2007;13(1):58-69. [Medline].

  29. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. Jun 2005;162(6):1142-8. [Medline].

  30. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. Dec 2009;124(6):1533-40. [Medline].

  31. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. Feb 2004;27(2):596-601. [Medline].

  32. King BH, Bostic JQ. An update on pharmacologic treatments for autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. Jan 2006;15(1):161-75. [Medline].

  33. King BH, Wright DM, Handen BL, Sikich L, Zimmerman AW, McMahon W, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. Jun 2001;40(6):658-65. [Medline].

  34. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. Apr 2009;46(4):266-71. [Medline]. [Full Text].

  35. Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. May 2008;23(5):482-5. [Medline].

  36. Saper RB, Phillips RS, Sehgal A, Khouri N, Davis RB, Paquin J, et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA. Aug 27 2008;300(8):915-23. [Medline]. [Full Text].

  37. Myers SM, Johnson CP. Management of children with autism spectrum disorders. Pediatrics. Nov 2007;120(5):1162-82. [Medline].

Previous
Next
 
Young child with fragile X syndrome who does not have obvious dysmorphic features.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.